

**2023高雄國際癌症研討會 議程表**

**2023 Kaohsiung International Cancer Symposium**

主辦單位：
台灣乳房醫學會、高雄醫學大學附設中和紀念醫院 乳房外科/癌症中心、社團法人高雄市乳癌防治衛教學會、高雄市醫事暨醫務行政學會 Organizers：
Taiwan Breast Cancer Society、Kaohsiung Medical University Chung-Ho Memorial Hospital Division of Breast Surgery / Cancer Center、Kaohsiung Breast Cancer Prevention and Education Society、Kaohsiung College of Healthcare Professionals and Executives
研討會日期：2023 年 4 月22 日(六) - 2023 年4月 23 日(日) Date: April 22 -23, 2023

研討會地點：高雄醫學大學附設中和紀念醫院啟川大樓六樓 第一講堂

 Venue: Auditorium I, 6F Building E, Kaohsiung Medical University Chung-Ho Memorial Hospital

|  |
| --- |
| **4月22 日(星期六) Saturday, 22 April** |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| **07:45-08:00** | 貴賓致詞 |
| **08:00-08:30** | Marker-guided effective therapy (Mget) | Mien-Chie Hung洪明奇 | Ming-Feng Hou侯明鋒 |
| **08:30-09:00** | Innovating precision care plan for chemotherapy-induced cytopenia, neuropathy, and sarcopenia through the neuroprotective mechanisms | Meng-Ru Shen沈孟儒 | Mien-Chie Hung洪明奇 |
| **09:00-09:30** | Proteogenomic Landscape of East-Asian Breast Cancer Reveals Pathogenesis and Subtypes for Prognostic and Therapeutic opportunities | Yu-Ju Chen陳玉如 | Lu-Hai Wang王陸海 |
| **09:30-10:00** | Mitochondrial Metabolism in Breast Cancer | Shyng-Shiou F. Yuan袁行修 | King-Jen Chang張金堅 |
| **10:00-10:20** | **Coffee Break** |
| **10:20-10:50** | Efficacy and Safety data of Sacituzumab govitecan in mTNBC and its Real-World Cases  | Hui-Ti See  | Shou-Tung Chen陳守棟 |
| **10:50-11:20** | An Optimized Treatment in High-risk HER2 negative early Breast Cancer | Chieh-Ni Kao高捷妮 | Chiun-Sheng Huang黃俊升 |
| **11:20-11:50** | Revision of adjuvant anthracycline chemotherapy in early breast cancer | Guo-Shiou Liao廖國秀 | Jyh-Cherng Yu俞志誠 |
| **11:50-12:20** | Identifying unmet needs for improving care for patients with chemotherapy-induced neutropenia | Jun-Ping Shiau蕭君平 | Guo-Shiou Liao廖國秀 |
| **12:20-13:30** | **Lunch** |
| **13:30-14:00** | Bone Health Management and SRE Prevention in Breast Cancer Patients: Experiences from NCKUH | Shuen-Ru Yang楊舜如 | Shin-Cheh Chen陳訓徹 |
| **14:00-14:30** | Reducing the risk of recurrence in HR+, HER2- early breast cancer | Wen-Ling Kuo郭玟伶 | Shyr-Ming Sheen-Chen沈陳石銘 |



|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| **14:30-15:00** | The maximization strategy from neoadjuvant to adjuvant in HER2 breast cancer | Liang-Chih Liu劉良智 | Ta-Chung Chao趙大中 |
| **15:00-15:30** | Striving for the optimal treatment outcome for the broadest set of patients in HR+HER2-mBC with CDK4/6i  | Huang-Po Hsiang黃柏翔 | Ling-Ming Tseng曾令民 |
| **15:30-15:50** | **Coffee Break**  |
| **15:50-16:20** | Fix Dose Combination for HER2 Dual Blockade: Deep Dive into Asian Experience | Huang Liang黃亮 | Yao-Lung Kuo郭耀隆 |
| **16:20-16:50** | CDK4/6i in HR+HER2-mBC pre-menopausal patient update  | Yu-Hsuan Kuo郭雨萱 | Liang-Chih Liu劉良智 |
| **16:50-17:20** | Give HER 1 More Chance ENHERTU as a New SOC in HER2 low | Chieh-Han Chuang莊捷翰 | Ming-Yang Wang王明暘 |
| **17:20-17:50** | The benefit of extended adjuvant therapy for HER2 Breast cancer | Hung-Wen Lai賴鴻文 | Dar-Ren Chen陳達人 |
| **17:50-18:00** | **Panel Discussion & Closing** |



|  |
| --- |
| **4 月 23 日(星期日) Sunday, 23 April** |
| **Breast Cancer** |
| **Time** | **Topic** | **Speaker** | **Moderator** |
| **08:00-08:30** | Improved systemic therapy for breast cancer | Shinji Ohno大野真司 | Chao-Ming Hung洪朝明Ching-Kuen Pan潘慶坤 |
| **08:30-09:00** | Differences between East and West on breast cancer treatment | Takashi Ishikawa石川孝 | Chen-Hsiang Chang張振祥Kuo-Ting Lee李國鼎 |
| **09:00-09:30** | Update on the establishment of a deep learning system for breast ultrasound diagnosis for clinical application | Tetsu Hayashida林田哲 | Kun-Ming Rau饒坤銘Yi-Chia Wu吳益嘉 |
| **09:30-10:00** | Combination treatment of Eribulin with Immulogy agent in TNBC treatment | Tomoharu Sugie杉江知治 | Wen-Hung Kuo郭文宏 |
| **10:00-10:20** | **Coffee Break** |
| **10:20-10:50** | Curability or irAE? Pros and Cons of ICI in peri-operative setting for TNBC | Ming-Shen Dai戴明燊 | Fu Ou-Yang 歐陽賦 |
| **10:50-11:20** | Efficacy and safety of nanoparticle-albumin-bound paclitaxel mono-chemotherapy for metastatic breast cancer | Hung-Wen Lai賴鴻文 | Chih-Jen Huang黃志仁 |
| **11:20-11:50** | Expanding the benefits of PARP inhibitors to more patients with advanced breast cancer | Wai-Shan Chung鍾煒珊 | Shen-Liang Shih施昇良 |
| **11:50-12:20** | New era of endocrien therapy in advanced breast cancer | An-Chieh Feng 馮安捷 | Fang-Ming Chen陳芳銘 |
| **12:20-12:30** | **Closing** | Fang-Ming Chen陳芳銘 |